Century Therapeutics announced two poster presentations at the ASGCT 27th Annual Meeting. The data presented highlights the potential of the Company’s lead candidate, CNTY-101, to treat B-cell driven autoimmune diseases including SLE. Additionally, the Company presented data which further demonstrates the capabilities of its Allo-Evasion technology through new preclinical data of a CD300a agonist which can potentially inhibit natural killer (NK) cell alloreactivity. Details of the posters are: Characterization of CNTY-101, an Allogeneic Anti-CD19 iPSC-Derived NK Product, for the Treatment of B Cell-Driven Autoimmune Diseases; and Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- Century Therapeutics price target lowered to $9 from $10 at Piper Sandler
- Century Therapeutics Executes Strategic Acquisition and Equity Sales
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Questions or Comments about the article? Write to editor@tipranks.com